Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity.
- That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
- Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery.
Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity (“PIRA”).
PIRA can occur at any point in the disease, even in early relapsing-remitting MS, and it challenges the old idea that relapsing and progressive MS are separate categories. Instead, evidence increasingly suggests MS behaves more like a continuum, with progressive biology present from the earliest stages of disease. As highly effective therapies have gotten better at stopping relapses, PIRA has become a larger share of the disability picture, since it keeps advancing even when relapse-based measures look calm.
That shift has forced researchers to look at what is actually driving PIRA. An important contributor is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. These are areas of demyelinated tissue surrounded by a rim of activated microglia and macrophages, often carrying iron, sitting behind a largely intact blood brain barrier. Unlike the acute inflammation behind a relapse, this activity is quiet and sustained, which is why researchers describe it as smoldering.
These lesions are not just a side observation. Their presence is linked to worse long-term prognosis and to the transition from relapsing to progressive disease, and they are associated with impaired remyelination and ongoing tissue injury. Because this inflammatory activity is compartmentalized within the central nervous system (“CNS”) behind a relatively intact blood-brain barrier, it may be less effectively modulated by therapies that primarily target peripheral immune activity.
This is why microglial activation and compartmentalized CNS inflammation have become such active areas of research. Persistent innate immune activation at the edge of these lesions appears to sustain tissue injury even when standard MRI and relapse measures look stable. Some researchers are now pushing for chronic active lesion measurements to be built directly into clinical trials, since conventional relapse-based and MRI endpoints may miss this slow-burning damage entirely.
The result is a research landscape that increasingly values confirmed disability progression, PIRA-specific endpoints and imaging of chronic active lesions alongside, or instead of, plain relapse counts. It also raises a strategic question for drug developers: a therapy that only quiets peripheral immune activity may leave the CNS’s own compartmentalized inflammation untouched.
Quantum BioPharma’s approach to Lucid-MS reflects that reasoning. Rather than broadly suppressing the immune system, the compound is designed to inhibit myelin degradation, preserve myelin and support functional recovery, aiming at the tissue-level damage rather than only the immune trigger behind a relapse. That distinction matters in a field where the most stubborn source of disability may not be stopped by immune suppression alone.
The company has also been developing tools to actually observe what is happening to myelin in real time. In June 2025, Quantum BioPharma and researchers at Massachusetts General Hospital scanned the first person with MS as part of a joint study validating a PET imaging technique for myelin integrity. The tracer involved was previously shown to be highly sensitive to demyelinated lesions in earlier animal and human studies. Tools like this could eventually help track chronic, low-grade myelin damage more directly than relapse counts or standard MRI scans currently allow.
In addition, Quantum BioPharma just received clearance to begin a phase 2 trial of Lucid-MS on patients with MS, following phase 1 studies that reported a favorable safety profile in healthy volunteers. The filing included data on pharmacology, toxicology and manufacturing quality, moving the program toward human efficacy testing for the very first time.
Lucid-MS remains an early-stage program, with its evidence to date coming from preclinical models rather than controlled human trials. But its underlying premise, that meaningful progress in MS depends on addressing tissue-level damage and not just circulating immune cells, lines up with where much of the field’s research attention is now headed. As disability progression takes center stage in how new MS therapies are judged, programs built around myelin protection and chronic CNS inflammation are likely to draw closer scrutiny, and Quantum BioPharma’s early work sits directly in that space.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity.
- That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
- Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery.
Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity (“PIRA”).
PIRA can occur at any point in the disease, even in early relapsing-remitting MS, and it challenges the old idea that relapsing and progressive MS are separate categories. Instead, evidence increasingly suggests MS behaves more like a continuum, with progressive biology present from the earliest stages of disease. As highly effective therapies have gotten better at stopping relapses, PIRA has become a larger share of the disability picture, since it keeps advancing even when relapse-based measures look calm.
That shift has forced researchers to look at what is actually driving PIRA. An important contributor is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. These are areas of demyelinated tissue surrounded by a rim of activated microglia and macrophages, often carrying iron, sitting behind a largely intact blood brain barrier. Unlike the acute inflammation behind a relapse, this activity is quiet and sustained, which is why researchers describe it as smoldering.
These lesions are not just a side observation. Their presence is linked to worse long-term prognosis and to the transition from relapsing to progressive disease, and they are associated with impaired remyelination and ongoing tissue injury. Because this inflammatory activity is compartmentalized within the central nervous system (“CNS”) behind a relatively intact blood-brain barrier, it may be less effectively modulated by therapies that primarily target peripheral immune activity.
This is why microglial activation and compartmentalized CNS inflammation have become such active areas of research. Persistent innate immune activation at the edge of these lesions appears to sustain tissue injury even when standard MRI and relapse measures look stable. Some researchers are now pushing for chronic active lesion measurements to be built directly into clinical trials, since conventional relapse-based and MRI endpoints may miss this slow-burning damage entirely.
The result is a research landscape that increasingly values confirmed disability progression, PIRA-specific endpoints and imaging of chronic active lesions alongside, or instead of, plain relapse counts. It also raises a strategic question for drug developers: a therapy that only quiets peripheral immune activity may leave the CNS’s own compartmentalized inflammation untouched.
Quantum BioPharma’s approach to Lucid-MS reflects that reasoning. Rather than broadly suppressing the immune system, the compound is designed to inhibit myelin degradation, preserve myelin and support functional recovery, aiming at the tissue-level damage rather than only the immune trigger behind a relapse. That distinction matters in a field where the most stubborn source of disability may not be stopped by immune suppression alone.
The company has also been developing tools to actually observe what is happening to myelin in real time. In June 2025, Quantum BioPharma and researchers at Massachusetts General Hospital scanned the first person with MS as part of a joint study validating a PET imaging technique for myelin integrity. The tracer involved was previously shown to be highly sensitive to demyelinated lesions in earlier animal and human studies. Tools like this could eventually help track chronic, low-grade myelin damage more directly than relapse counts or standard MRI scans currently allow.
In addition, Quantum BioPharma just received clearance to begin a phase 2 trial of Lucid-MS on patients with MS, following phase 1 studies that reported a favorable safety profile in healthy volunteers. The filing included data on pharmacology, toxicology and manufacturing quality, moving the program toward human efficacy testing for the very first time.
Lucid-MS remains an early-stage program, with its evidence to date coming from preclinical models rather than controlled human trials. But its underlying premise, that meaningful progress in MS depends on addressing tissue-level damage and not just circulating immune cells, lines up with where much of the field’s research attention is now headed. As disability progression takes center stage in how new MS therapies are judged, programs built around myelin protection and chronic CNS inflammation are likely to draw closer scrutiny, and Quantum BioPharma’s early work sits directly in that space.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
